Recognition and Management of Polymyalgia Rheumatica and Giant Cell Arteritis



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2013 Nov 15;88(10):676-684.

This clinical content conforms to AAFP criteria for continuing medical education (CME). See the CME Quiz.

  Patient information: See related handout on polymyalgia rheumatica and giant cell arteritis, written by the authors of this article.

Author disclosure: No relevant financial affiliations.

Polymyalgia rheumatica affects proximal muscles and joints, causing disability in older adults. Giant cell arteritis affects medium and large arteries and can result in blindness. These conditions overlap significantly, often occurring together. Despite the similarities, each has distinct symptoms, corticosteroid dosing requirements, and prognosis. The hallmark of both conditions is inflammation. Polymyalgia rheumatica primarily affects the shoulders, neck, and hips with prominent bilateral pain. Systemic findings such as fatigue and weight loss are common, and there is no definitive diagnostic test. Moderate-dose corticosteroid therapy with a slow taper rapidly resolves symptoms. Management of patients responding to treatment can occur in the primary care setting, if there is no concomitant giant cell arteritis. The clinical presentation of giant cell arteritis varies widely, from new-onset headache and constitutional symptoms, to jaw claudication, to less common isolated visual changes and upper extremity claudication. Treatment requires higher dosages of corticosteroids and urgent referral to a rheumatologist. Relapse is common in both diseases. Surveillance is important, as is monitoring for long-term complications of corticosteroid use. Osteoporosis management and gastrointestinal ulcer prophylaxis should be initiated. The primary care physician's coordination of care with a rheumatologist and with other subspecialists, if needed, is essential in the management of giant cell arteritis.

Polymyalgia rheumatica, the most common chronic inflammatory condition in older adults, primarily affects proximal muscles and joints, causing disability. Giant cell arteritis, the most common type of vasculitis in adults, affects medium and large arteries and can result in blindness.1,2 These conditions often occur together and are among the most common diseases that necessitate long-term corticosteroid use in older adults.3,4 They are often identified and treated, at least in part, by the primary care physician. Polymyalgia rheumatica is two to three times more common than giant cell arteritis,3 but there is significant overlap between the two conditions. Approximately 18% to 26%3,5 of cases of polymyalgia rheumatica involve giant cell arteritis; conversely, 27% to 53%6,7 of cases of giant cell arteritis involve polymyalgia rheumatica. Polymyalgia rheumatica can occur before, with, or after the emergence of giant cell arteritis.8

Both conditions affect similar populations (typically older white persons of Northern European descent).5 The prevalence varies by age and population. In areas with higher concentrations of persons of Northern European descent and in persons older than 50 years, the prevalence is one in 143 persons for polymyalgia rheumatica and one in 500 for giant cell arteritis.9 The incidence of both conditions increases with age, peaking between 70 and 80 years of age.3 Women are two to three times more likely than men to be affected by either condition.1,5 Blacks, Asians, and Alaska natives have a much lower incidence of these diseases.3,10,11 Despite their similarities, polymyalgia rheumatica and giant cell arteritis have distinct symptoms, corticosteroid requirements, and prognoses. When the conditions occur together, the higher corticosteroid doses used to treat giant cell arteritis are needed to prevent significant complications.12

The hallmark of these conditions is inflammation.3,13 The etiologies are not clearly defined. Environmental exposures and genetics both play a role, with antigen-mediated inflammation the likely culprit.3,13 Seasonal, cyclical variations implicate infectious agents (e.g., viruses, Mycoplasma pneumoniae) as triggers, although specific pathogens have not yet been identified.13 Until recently, evidence of actual muscle inflammation was lacking in polymyalgia rheumatica, given normal muscle enzymes and inconsistent immunohistologic findings or vasculitis.14,15 Traditionally, inflammation was thought to be limited to the synovial and bursal linings.14,16 However, inflammatory cytokines have now been found in symptomatic muscles, indicating muscle involvement.17 In giant cell arteritis, inflammation affects medium and large arteries.1 Histologically, focal and segmental lesions are characterized by granulomatous, inflammatory infiltrates at the intimamedia junction that form skip lesions.18

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Straightforward polymyalgia rheumatica should be treated with low-dose corticosteroids and a slow taper.

C

20, 24

Prednisone in a starting dosage of 15 mg per day is the consensus recommendation.

Medications should be instituted to decrease fracture risk in patients on high-dose, long-term glucocorticoid therapy.

B

3032

Alendronate (Fosamax) and risedronate (Actonel) have been shown to increase bone mineral density and decrease vertebral fractures in patients on long-term glucocorticoid

The Authors

TONYA L. CAYLOR, MD, is a faculty member at the Alaska Family Medicine Residency in Anchorage. She is also a clinical assistant professor in the Department of Family Medicine at the University of Washington School of Medicine in Seattle.

ALLEN PERKINS, MD, MPH, is a professor in and chair of the Department of Family Medicine at the University of South Alabama in Mobile.

Address correspondence to Allen Perkins, MD, MPH, University of South Alabama, 1504 Springhill Ave., Ste. 3414, Mobile, AL 36604. Reprints are not available from the authors.

REFERENCES

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–271.

2. Butler N, Mundy J, Shah P. Aortic complications of giant cell arteritis: a diagnostic and management dilemma. J Card Surg. 2010;25(5):572–581.

3. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991;34(3):351–356.

4. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–1838.

5. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum. 1995;38(3):369–373.

6. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol. 2011;30(2):259–262.

7. Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5(3):205–215.

8. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–245.

9. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778–799.

10. Pereira LS, Yoon MK, Hwang TN, et al. Giant cell arteritis in Asians: a comparative study. Br J Ophthalmol. 2011;95(2):214–216.

11. Mader TH, Werner RP, Chamberlain DG, Doornbos D. Giant cell arteritis in Alaska Natives. Can J Ophthalmol. 2009;44(1):53–56.

12. Font C, Cid MC, Coll-Vinent B, López-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997;36(2):251–254.

13. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996;23(1):112–119.

14. Camellino D, Sambuceti G, Morbelli S, Cimmino MA. Clinical images: the multifaceted pathogenesis of polymyalgia rheumatica/giant cell arteritis. Arthritis Rheum. 2009;60(9):2771.

15. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007;46(4):672–677.

16. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23(4):462–468.

17. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010;62(12):3768–3775.

18. Lie JT; American College of Rheumatology Subcommittee on Classification of Vasculitis. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum. 1990;33(8):1074–1087.

19. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97(5):672–680.

20. Dasgupta B, Borg FA, Hassan N, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–190.

21. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286(6361):266.

22. Schmidt WA, Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology (Oxford). 2002;41(1):46–52.

23. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17–24.

24. Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169(20):1839–1850.

25. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with poly-myalgia rheumatica. J Rheumatol. 2005;32(1):65–73.

26. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford). 2010;49(4):716–722.

27. Spies CM, Burmester GR, Buttgereit F. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. Clin Exp Rheumatol. 2010;28(5 suppl 61):S172–S177.

28. Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176.

29. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med. 2007;146(9):631–639.

30. Saag KG, Emkey R, Schnitzer TJ, et al.; Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299.

31. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.

32. Reid DM, Devogelaer JP, Saag K, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–1263.

33. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–1128.

34. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92–101.

35. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum. 2001;45(2):140–145.

36. Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009;36(4):794–796.

37. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123(3):192–194.

38. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). 2005;84(5):277–290.

39. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–296.

40. Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation. Medicine (Baltimore). 2008;87(1):45–51.

41. Wilson H, Alderson DJ. Sudden sensorineural hearing loss: when is it idiopathic? J Laryngol Otol. 2010;124(6):690–693.

42. Dasgupta B, Borg FA, Hassan N, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–1597.

43. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987–992.

44. Zhou L, Luneau K, Weyand CM, Biousse V, Newman NJ, Grossniklaus HE. Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology. 2009;116(8):1574–1580.

45. Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford). 2008;47(4):488–490.

46. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142(5):359–369.

47. Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol. 2000;18(4 suppl 20):S43–S48.

48. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–1337.

49. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–2797.

50. Hoffman GS, Cid MC, Rendt-Zagar KE, et al.; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–630.

51. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.

52. Assie C, Janvresse A, Plissonnier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90(1):40–51.

53. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102–1106.


Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

More in Pubmed

Navigate this Article